BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cetuximab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cetuximab\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06943820-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT06943820)
DESCRIPTION:Cetuximab\, phase 1/2\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: AK129 Combination Therapy for Advanced Solid Tumors\nEstimated pri
 mary completion: December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06943820
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06915142-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06915142)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: A Phase II Clinical Study of HRS-7
 058 in Combination With Antitumor Drugs in Patients With Advanced Malignan
 t Tumour\nEstimated primary completion: December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06915142
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04375384-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT04375384)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Cetuximab After Immunotherapy for the Treatment of Head and Neck Squ
 amous Cell Cancer\nEstimated primary completion: December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04375384
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01025089-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT01025089)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Chemotherapy Plus Cetuximab Follow
 ed by Surgical Resection in Patients With Locally Advanced or Recurrent Th
 ymoma or Thymic Carcinoma\nEstimated primary completion: December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT01025089
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03803553-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cetuximab: Phase 3 readout est. (NCT03803553)
DESCRIPTION:Cetuximab\, phase 3.\nStudy: Identification and Treatment Of Mi
 crometastatic Disease in Stage III Colon Cancer\nEstimated primary complet
 ion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 etuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03803553
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998069-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Cetuximab: Phase 3 readout est. (NCT06998069)
DESCRIPTION:Cetuximab\, phase 3\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Head and Neck Cancer Study Project in the Geriatric Population\nEsti
 mated primary completion: 1 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06998069
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797336-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Cetuximab: Phase 1 readout est. (NCT06797336)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: A Study of PT0253 in Participants 
 With KRAS G12D Mutated Advanced Solid Tumors\nEstimated primary completion
 : 15 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 etuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06797336
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05706779-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Cetuximab: Phase 2 readout est. (NCT05706779)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Encorafenib Plus Cetuximab in a Ne
 oadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper 
 Rectum Cancer\nEstimated primary completion: 30 December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05706779
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06321081-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06321081)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: ICE
  Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rech
 allenge Regimen in mCRC\nEstimated primary completion: 30 December 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06321081
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06763029-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06763029)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Irinotecan Liposomes Combined with
  Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cance
 r\nEstimated primary completion: 31 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06763029
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07257653-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07257653)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: The
  Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without I
 mmune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type
  Unresectable Metastatic Colorectal Cancer\nEstimated primary completion: 
 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cet
 uximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07257653
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05959356-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT05959356)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: Cet
 uximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRA
 F Wild-type\, MSS\, Unresectable Left-side Metastatic Colorectal Cancer\nE
 stimated primary completion: 31 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05959356
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06239220-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06239220)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: PD-L1 t-haNK\, NAI IL-15sa and Cetuximab for Recurrent\, Metastatic 
 HNSCC\nEstimated primary completion: 31 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06239220
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06226857-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cetuximab: Phase 3 readout est. (NCT06226857)
DESCRIPTION:Cetuximab\, phase 3\, Metastatic Colorectal Cancer.\nStudy: Oth
 er Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided R
 AS-wild Type Metastatic Colorectal Cancer\nEstimated primary completion: 3
 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetu
 ximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06226857
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06179160-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Cetuximab: Phase 1 readout est. (NCT06179160)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: A Study to Evaluate INCB161734 in 
 Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutat
 ion\nEstimated primary completion: 1 January 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06179160
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06715124-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270102
DTEND;VALUE=DATE:20270103
SUMMARY:Cetuximab: Phase 1 readout est. (NCT06715124)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: QTX3544 in Patients With Advanced 
 Solid Tumors With KRAS G12V Mutations\nEstimated primary completion: 2 Jan
 uary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0671
 5124
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05584670-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270120
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT05584670)
DESCRIPTION:Cetuximab\, phase 1/2.\nStudy: A First-in-human\, Dose Escalati
 on and Dose Expansion Study of SAR445877 in Adult Participants With Advanc
 ed Solid Tumors\nEstimated primary completion: 19 January 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05584670
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06102902-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Cetuximab: Phase 1 readout est. (NCT06102902)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: Testing the Addition of Anti-cance
 r Drug\, ZEN003694\, to the Usual Chemotherapy Treatment\, Cetuximab Plus 
 Encorafenib\, for Colorectal Cancer\nEstimated primary completion: 30 Janu
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06102
 902
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059949-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07059949)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Short Course Radiotherapy Followed
  by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Tr
 eatment of Unresectable Metastatic Rectal Cancer\nEstimated primary comple
 tion: 30 January 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/cetuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07059949
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07327411-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07327411)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Cetuximab β Combined With PRaG Re
 gimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors\n
 Estimated primary completion: 10 February 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07327411
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059221-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT07059221)
DESCRIPTION:Cetuximab\, phase 1/2\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-t
 umor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinom
 a Cancer\nEstimated primary completion: March 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07059221
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06818812-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270327
DTEND;VALUE=DATE:20270328
SUMMARY:Cetuximab: Phase 1 readout est. (NCT06818812)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: A Study to Evaluate INCB186748 in 
 Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutat
 ion\nEstimated primary completion: 27 March 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06818812
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06978829-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06978829)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Cetuximab + Tislelizumab + Chemoth
 erapy in the Treatment of Unresectable LA HNSCC\nEstimated primary complet
 ion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 etuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06978829
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05410145-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT05410145)
DESCRIPTION:Cetuximab\, phase 1/2.\nStudy: A Study of D3S-001 Monotherapy o
 r Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p
 .G12C Mutation\nEstimated primary completion: April 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05410145
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06227377-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Cetuximab: Phase 1 readout est. (NCT06227377)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: QTX3034 in Patients With KRAS G12D
  Mutation\nEstimated primary completion: 1 April 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06227377
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06411600-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06411600)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: Com
 bination Therapy for BRAF-V600E Metastatic CRCm\nEstimated primary complet
 ion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetu
 ximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06411600
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06448026-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06448026)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Cemiplimab and Cetuximab Prior Sal
 vage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oroph
 aryngeal Squamous Cell Carcinoma\nEstimated primary completion: 15 May 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06448026
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07000305-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270520
DTEND;VALUE=DATE:20270521
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07000305)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: A Study of Cetuximabβ Combined Wi
 th Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer\nEst
 imated primary completion: 20 May 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07000305
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07559760-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07559760)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: New
  Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer\nEstimated
  primary completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07559760
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06959589-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06959589)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: The
  Efficacy and Safety of IBI351\, Cetuximab β Combined With FOLFIRI as Fir
 st-line /IBI351\, Cetuximab β as Second-line in the Treatment of KRAS G12
 C-mutated Metastatic Colorectal Cancer\nEstimated primary completion: 31 M
 ay 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069595
 89
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07644559-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07644559)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: A Phase 2 Study of VS-7375 in Pati
 ents With KRAS G12D-Mutated Pancreatic Cancer\nEstimated primary completio
 n: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuxim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7644559
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07659795-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07659795)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: A Phase 2 Study of VS-7375 in Pati
 ents With KRAS G12D-Mutated Colorectal Cancer\nEstimated primary completio
 n: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuxim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7659795
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04485013-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Cetuximab: Phase 1 readout est. (NCT04485013)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: TTX-080 HLA-G Antagonist in Subjec
 ts With Advanced Cancers\nEstimated primary completion: 1 June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04485013
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06912087-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270605
DTEND;VALUE=DATE:20270606
SUMMARY:Cetuximab: Phase 1 readout est. (NCT06912087)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: Dose Finding Study of Zanzalintini
 b With Pembrolizumab and Cetuximab in Head and Neck SCC\nEstimated primary
  completion: 5 June 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/cetuximab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06912087
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04722523-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270620
DTEND;VALUE=DATE:20270621
SUMMARY:Cetuximab: Phase 1 readout est. (NCT04722523)
DESCRIPTION:Cetuximab\, phase 1\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: A Study of Cemiplimab With Chemotherapy and Immunotherapy in People 
 With Head and Neck Cancer\nEstimated primary completion: 20 June 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT04722523
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07302841-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270620
DTEND;VALUE=DATE:20270621
SUMMARY:Cetuximab: Phase 4 readout est. (NCT07302841)
DESCRIPTION:Cetuximab\, phase 4.\nStudy: Tunlametinib + AG + Cetuximab β a
 s First-Line Therapy for Advanced Pancreatic Cancer\nEstimated primary com
 pletion: 20 June 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/cetuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07302841
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07543471-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Cetuximab: Phase 1 readout est. (NCT07543471)
DESCRIPTION:Cetuximab\, phase 1\, Metastatic Colorectal Cancer.\nStudy: A P
 hase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HL
 X05-N vs. ERBITUX® in Metastatic Colorectal Cancer\nEstimated primary com
 pletion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/cetuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07543471
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07259590-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT07259590)
DESCRIPTION:Cetuximab\, phase 1/2.\nStudy: A Study of GFH375 Combined With 
 Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS
  G12D Mutation\nEstimated primary completion: July 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07259590
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07079410-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07079410)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Neoadjuvant and Adjuvant Sintilima
 b Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell 
 Carcinoma\nEstimated primary completion: July 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07079410
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428500-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Cetuximab: Phase 1 readout est. (NCT06428500)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: QTX3046 in Patients With KRAS G12D
  Mutations\nEstimated primary completion: 1 July 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06428500
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06917079-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Cetuximab: Phase 1 readout est. (NCT06917079)
DESCRIPTION:Cetuximab\, phase 1\, Metastatic Colorectal Cancer.\nStudy: BBO
 -11818 in Adult Subjects With KRAS Mutant Cancer\nEstimated primary comple
 tion: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ce
 tuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06917079
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06869473-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270820
DTEND;VALUE=DATE:20270821
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06869473)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Cetuximab Plus Platinum and Taxane-based Chemotherapy\, Followed by 
 Avelumab and Cetuximab\, as First-line Treatment for Recurrent/Metastatic 
 Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combin
 ed Positive Score (CPS)≥1≤19.\nEstimated primary completion: 20 August
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06869473
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06806852-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Cetuximab: Phase 1 readout est. (NCT06806852)
DESCRIPTION:Cetuximab\, phase 1\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: A Study to Test Whether Treatment With BI 770371 in Combination With
  Pembrolizumab With or Without Cetuximab Helps People With Head and Neck C
 ancer Compared With Pembrolizumab Alone\nEstimated primary completion: 31 
 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuxima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 806852
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05722327-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Cetuximab: Phase 1 readout est. (NCT05722327)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: Phase I Trial of Adagrasib (MRTX84
 9) in Combination With Cetuximab and Irinotecan in Patients With Colorecta
 l Cancer\nEstimated primary completion: 30 September 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05722327
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07474727-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07474727)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: A Phase II Study of AMT-676 Combin
 ation Therapies in Advanced Colorectal Cancer\nEstimated primary completio
 n: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /cetuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07474727
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06640725-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20271002
DTEND;VALUE=DATE:20271003
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06640725)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab 
 in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N\n
 Estimated primary completion: 2 October 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06640725
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764771-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Cetuximab: Phase 1 readout est. (NCT06764771)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: A Study of BMS-986488 as Monothera
 py and Combination Therapy in Participants With Advanced Malignant Tumors\
 nEstimated primary completion: 15 October 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06764771
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07446270-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07446270)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Efficacy of Tunlametinib in Combin
 ation With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Adva
 nced Gastrointestinal Malignancies\nEstimated primary completion: 30 Octob
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074462
 70
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07678593-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT07678593)
DESCRIPTION:Cetuximab\, phase 1/2.\nStudy: A Study of GFH276 Combined With 
 Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic
  Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation\nEstimated primary co
 mpletion: November 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/cetuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07678593
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06978400-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20271110
DTEND;VALUE=DATE:20271111
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06978400)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: A S
 tudy of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Lin
 e of Therapy in People With Metastatic Colorectal Cancer\nEstimated primar
 y completion: 10 November 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06978400
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318389-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20271114
DTEND;VALUE=DATE:20271115
SUMMARY:Cetuximab: Phase 1 readout est. (NCT07318389)
DESCRIPTION:Cetuximab\, phase 1\, Metastatic Colorectal Cancer.\nStudy: ASC
 END-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With
  Metastatic Colorectal Cancer\nEstimated primary completion: 14 November 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07318389
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07506109-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07506109)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: A P
 hase II Study of Sintilimab Combined With Ipilimumab N01\, Cetuximab and D
 abrafenib in Patients With Microsatellite-Stable\, BRAF V600E-Mutated Meta
 static Colorectal Cancer\nEstimated primary completion: December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07506109
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02999087-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cetuximab: Phase 3 readout est. (NCT02999087)
DESCRIPTION:Cetuximab\, phase 3.\nStudy: Randomized Trial of Avelumab-cetux
 imab-radiotherapy Versus SOCs in LA SCCHN (REACH)\nEstimated primary compl
 etion: December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /cetuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT02999087
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06865664-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Cetuximab: Phase 1 readout est. (NCT06865664)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: FGFR4 Chimeric Antigen Receptor (C
 AR) T Cells in Children and Young Adults With Recurrent or Refractory Rhab
 domyosarcoma\nEstimated primary completion: 1 December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06865664
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05910827-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT05910827)
DESCRIPTION:Cetuximab\, phase 1/2\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: A Phase Ib/II Study of an Anti-HER3 Antibody\, HMBD-001\, With Cet
 uximab +/- Docetaxel in Advanced Squamous Cell Cancers\nEstimated primary 
 completion: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/cetuximab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05910827
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05063552-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Cetuximab: Phase 2/3 readout est. (NCT05063552)
DESCRIPTION:Cetuximab\, phase 2/3\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: Testing the Use of Investigational Drugs Atezolizumab and/or Bevac
 izumab With or Without Standard Chemotherapy in the Second-Line Treatment 
 of Advanced-Stage Head and Neck Cancers\nEstimated primary completion: 15 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuxi
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05063552
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04017650-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT04017650)
DESCRIPTION:Cetuximab\, phase 1/2\, Metastatic Colorectal Cancer.\nStudy: E
 ncorafenib\, Cetuximab\, and Nivolumab in Treating Patients With Microsate
 llite Stable\, BRAFV600E Mutated Unresectable or Metastatic Colorectal Can
 cer\nEstimated primary completion: 30 December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04017650
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059338-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07059338)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: Dua
 l EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Po
 sitive Metastatic Colorectal Cancer\nEstimated primary completion: 30 Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0705
 9338
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06540261-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cetuximab: Phase 1 readout est. (NCT06540261)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: The Study of ONO-7913\, ONO-4538 a
 nd the Standard of Care as First-line Treatment in Patients Colorectal Can
 cer\nEstimated primary completion: 31 December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06540261
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07012954-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT07012954)
DESCRIPTION:Cetuximab\, phase 1/2.\nStudy: ctDNA-Guided Cetuximab or Bevaci
 zumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC\nEstimated pr
 imary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07012954
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03391843-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT03391843)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Neoadjuvant Chemotherapy Combined 
 With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer\nEstimate
 d primary completion: 31 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03391843
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07618624-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07618624)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: BRIDGE Study: Neoadjuvant Finotonlimab\, Cetuximab\, and Docetaxel i
 n Resectable Recurrent HNSCC After Immunotherapy Progression\nEstimated pr
 imary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07618624
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01154920-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT01154920)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Paclitaxel\, Carboplatin and Cetuximab (PCC) With Cetuximab\, Doceta
 xel\, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients 
 With Locally Advanced Head and Neck Squamous Cell Carcinoma\nEstimated pri
 mary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT01154920
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07216105-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Cetuximab: Phase 1 readout est. (NCT07216105)
DESCRIPTION:Cetuximab\, phase 1\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: FT836 With or Without Chemotherapy and/or Monoclonal Antibodies\, in
  Participants With Advanced Solid Tumors\nEstimated primary completion: Ja
 nuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072
 16105
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06725368-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06725368)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembroli
 zumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Ca
 rcinoma of the Head and Neck\nEstimated primary completion: January 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06725368
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06771622-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT06771622)
DESCRIPTION:Cetuximab\, phase 1/2.\nStudy: Safety and Efficacy of HCB101 in
  Combination With Multiple Agents in Patients With Advanced Solid Tumors\n
 Estimated primary completion: 1 January 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06771622
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07063212-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280102
DTEND;VALUE=DATE:20280103
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07063212)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: A Study of Sacituzumab Govitecan in Combination With Cetuximab in Pe
 ople With Head and Neck Squamous Cell Cancer (HNSCC)\nEstimated primary co
 mpletion: 2 January 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/cetuximab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07063212
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07672483-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Cetuximab: Phase 1 readout est. (NCT07672483)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: IL-12 Genetically Engineered Myelo
 id Cells in Participants With Relapsed\, Refractory Solid Tumors\nEstimate
 d primary completion: 15 January 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07672483
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07415031-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280216
DTEND;VALUE=DATE:20280217
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07415031)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: A Solid Tumor Study for Long Term 
 Treatment of Cancer Patients Who Participated in Adagrasib Studies\nEstima
 ted primary completion: 16 February 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07415031
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06855212-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06855212)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients U
 ndergoing Surgery for HNSCC\nEstimated primary completion: March 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06855212
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07094893-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Cetuximab: Phase 4 readout est. (NCT07094893)
DESCRIPTION:Cetuximab\, phase 4.\nStudy: Anti-EGFR Agents in Patients With 
 Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG Hi
 gh Status\nEstimated primary completion: March 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07094893
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05985954-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280328
DTEND;VALUE=DATE:20280329
SUMMARY:Cetuximab: Phase 1 readout est. (NCT05985954)
DESCRIPTION:Cetuximab\, phase 1\, Metastatic Colorectal Cancer.\nStudy: Ope
 n-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Comb
 ination With Cetuximab and Encorafenib in Patients With Unresectable or Me
 tastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-direc
 ted Therapy\nEstimated primary completion: 28 March 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05985954
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503639-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07503639)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Umbrella Trial of Neoadjuvant Ther
 apy for Locally Advanced Colorectal Cancer\nEstimated primary completion: 
 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075
 03639
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07915921-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT07915921)
DESCRIPTION:Cetuximab\, phase 1/2\, Metastatic Colorectal Cancer.\nStudy: A
  Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizu
 mab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer
 \nEstimated primary completion: 30 April 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07915921
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07490119-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07490119)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Becotatug Vedotin Combined With Ce
 tuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal
  Cancer\nEstimated primary completion: 1 June 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07490119
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683403-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT07683403)
DESCRIPTION:Cetuximab\, phase 1/2\, Metastatic Colorectal Cancer.\nStudy: S
 avolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type M
 etastatic Colorectal Cancer\nEstimated primary completion: 30 June 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07683403
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04892173-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Cetuximab: Phase 3 readout est. (NCT04892173)
DESCRIPTION:Cetuximab\, phase 3.\nStudy: JNJ-90301900 (NBTXR3) Activated by
  Radiotherapy With or Without Cetuximab in LA-HNSCC\nEstimated primary com
 pletion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/cetuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04892173
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874438-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Cetuximab: Phase na readout est. (NCT07874438)
DESCRIPTION:Cetuximab\, phase na\, Metastatic Colorectal Cancer.\nStudy: A 
 Prospective\, Single-Arm\, Multicenter\, Phase II Clinical Study of Iparom
 limab and Tuvonralimab (QL1706) Combined With Cetuximab and mFOLFIRI Regim
 en as First-Line Treatment for Recurrent or Metastatic Colorectal Cancer\n
 Estimated primary completion: 30 June 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07874438
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07896681-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07896681)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Toripalimab Plus Cetuximab and Iri
 notecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Canc
 er Phase II Study\nEstimated primary completion: 1 July 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07896681
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722754-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07722754)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: Bev
 acizumab\, Sintilimab\, Cetuximab and Irinotecan in Refractory RAS Wild-ty
 pe Metastatic Colorectal Cancer: BOND-4 Trial\nEstimated primary completio
 n: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetu
 ximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07722754
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06440902-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06440902)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: Exp
 loration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorec
 tal Cancer Based on Circulating Tumor DNA\nEstimated primary completion: 1
  September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetu
 ximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06440902
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05041127-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Cetuximab: Phase 2 readout est. (NCT05041127)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Cetuximab for the Treatment of Adv
 anced Unresectable or Metastatic Chordoma\nEstimated primary completion: 1
  September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetu
 ximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05041127
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07746141-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Cetuximab: Phase 1 readout est. (NCT07746141)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: A First-in-Human Study Investigati
 ng BG-85738 Alone or in Combination With Other Antitumor Agents in Patient
 s With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mu
 tations\nEstimated primary completion: 30 September 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07746141
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06445062-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT06445062)
DESCRIPTION:Cetuximab\, phase 1/2.\nStudy: Study of RAS(ON) Inhibitors in P
 atients With Gastrointestinal Solid Tumors\nEstimated primary completion: 
 30 September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ce
 tuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06445062
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616259-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Cetuximab: Phase 3 readout est. (NCT06616259)
DESCRIPTION:Cetuximab\, phase 3.\nStudy: First-line Treatment of MCapOX + C
 etuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type\, MSS\, Unresecta
 ble Left-Sided MCRC: a Multicenter\, Randomized\, Controlled\, Phase III S
 tudy\nEstimated primary completion: 30 September 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06616259
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06856213-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06856213)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To
  First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Met
 astatic Squamous Cell Carcinoma of the Head and Neck.\nEstimated primary c
 ompletion: October 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/cetuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06856213
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06551142-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20281016
DTEND;VALUE=DATE:20281017
SUMMARY:Cetuximab: Phase 1 readout est. (NCT06551142)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: A Study of GSK5764227 in Participa
 nts With Advanced Solid Tumors (EMBOLD)\nEstimated primary completion: 16 
 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuxim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6551142
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07882888-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20281016
DTEND;VALUE=DATE:20281017
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07882888)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Iparomlimab and Tuvonralimab With With Cetuximab in Resectable OSCC\
 nEstimated primary completion: 16 October 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07882888
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07912593-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT07912593)
DESCRIPTION:Cetuximab\, phase 1/2\, Metastatic Colorectal Cancer.\nStudy: A
  KRAS Inhibitor in Participants With Advanced Solid Tumors\nEstimated prim
 ary completion: 30 October 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07912593
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973564-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT06973564)
DESCRIPTION:Cetuximab\, phase 1/2.\nStudy: JAB-23E73 in Adult Participants 
 With Advanced Solid Tumors With KRAS Alteration\nEstimated primary complet
 ion: November 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 etuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06973564
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07814417-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07814417)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: A Study of Olomorasib (LY3537982) 
 in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation\n
 Estimated primary completion: November 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07814417
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07913360-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Cetuximab: Phase 3 readout est. (NCT07913360)
DESCRIPTION:Cetuximab\, phase 3\, Metastatic Colorectal Cancer.\nStudy: GFH
 375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Muta
 nt Refractory Metastatic Colorectal Cancer\nEstimated primary completion: 
 November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuxi
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07913360
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07411599-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20281115
DTEND;VALUE=DATE:20281116
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT07411599)
DESCRIPTION:Cetuximab\, phase 1/2.\nStudy: Dual Administration Of Intraperi
 toneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGF
 BR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carci
 nomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")\nEstimated primary complet
 ion: 15 November 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/cetuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07411599
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02861898-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT02861898)
DESCRIPTION:Cetuximab\, phase 1/2.\nStudy: Super-selective Intra-arterial R
 epeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Gliobla
 stoma\nEstimated primary completion: December 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT02861898
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581912-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07581912)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Neoadjuvant Treatment of Fulzerasi
 b Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Canc
 er With or Without Resectable Metastases\nEstimated primary completion: De
 cember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuxima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 581912
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05382559-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cetuximab: Phase 1 readout est. (NCT05382559)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: A Study of ASP3082 in Adults With 
 Advanced Solid Tumors\nEstimated primary completion: 31 December 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05382559
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04616183-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT04616183)
DESCRIPTION:Cetuximab\, phase 1/2\, Metastatic Colorectal Cancer.\nStudy: L
 Y3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Tr
 eatment of Unresectable or Metastatic Colorectal Cancer\nEstimated primary
  completion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04616183
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06935188-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06935188)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negat
 ive\, Anti-PD-1-resistant R/M HNSCC\nEstimated primary completion: 31 Dece
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0693
 5188
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06706401-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Cetuximab: Phase 3 readout est. (NCT06706401)
DESCRIPTION:Cetuximab\, phase 3.\nStudy: Lymphocyte-Sparing And Radio-Immun
 otherapy in Head and Neck Carcinoma\nEstimated primary completion: January
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06706401
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06358430-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20290118
DTEND;VALUE=DATE:20290119
SUMMARY:Cetuximab: Phase 1 readout est. (NCT06358430)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: Dose Escalation and Expansion Stud
 y of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in
  Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With M
 inimal Residual Disease (MRD)\nEstimated primary completion: 18 January 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06358430
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06369259-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06369259)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Open-label Phase 2 Study of Avutom
 etinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and 
 Cetuximab in Patients With Unresectable\, Anti-EGFR-Refractory Advanced Co
 lorectal Cancer\nEstimated primary completion: 1 February 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06369259
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06412198-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT06412198)
DESCRIPTION:Cetuximab\, phase 1/2\, Metastatic Colorectal Cancer.\nStudy: A
  Multicenter Phase 1b/2 Study of Adagrasib\, Cetuximab\, and Cemiplimab fo
 r Metastatic Colorectal Cancer Harboring KRAS G12C Mutations\nEstimated pr
 imary completion: 1 March 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06412198
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06997497-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20290328
DTEND;VALUE=DATE:20290329
SUMMARY:Cetuximab: Phase 3 readout est. (NCT06997497)
DESCRIPTION:Cetuximab\, phase 3.\nStudy: A Clinical Study of Calderasib (MK
 -1084) With Targeted Therapy and Chemotherapy in People With Colorectal Ca
 ncer (MK-1084-012/KANDLELIT-012)\nEstimated primary completion: 28 March 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06997497
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07217028-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Cetuximab: Phase 1 readout est. (NCT07217028)
DESCRIPTION:Cetuximab\, phase 1\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Ind
 eterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cel
 l Carcinoma\nEstimated primary completion: April 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07217028
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06207656-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06207656)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Study to Evaluate the Efficacy and
  Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As I
 nduction Treatment in BRAF V600E Mutated MSS Initially Resectable or Poten
 tially Resectable Advanced Colorectal Cancer\nEstimated primary completion
 : 1 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetux
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06207656
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318805-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20290414
DTEND;VALUE=DATE:20290415
SUMMARY:Cetuximab: Phase 1 readout est. (NCT07318805)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: A Study to Learn About the Study M
 edicine Called PF-08032562 in People With Advanced or Metastatic Solid Tum
 ors\nEstimated primary completion: 14 April 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07318805
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07549399-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Cetuximab: Phase 3 readout est. (NCT07549399)
DESCRIPTION:Cetuximab\, phase 3.\nStudy: SCRT + Chemo Targeted Immuno-neoad
 juvant Therapy for High-risk pMMR/MSS RC\nEstimated primary completion: 30
  April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuxima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 549399
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06241456-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Cetuximab: Phase 1 readout est. (NCT06241456)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: FT825/ONO-8250\, an Off-the-Shelf\
 , HER2 CAR-T\, With or Without Monoclonal Antibodies in Advanced Solid Tum
 ors\nEstimated primary completion: 1 May 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06241456
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05836324-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20290503
DTEND;VALUE=DATE:20290504
SUMMARY:Cetuximab: Phase 1 readout est. (NCT05836324)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: A Study to Evaluate the Safety of 
 INCA33890 in Participants With Advanced or Metastatic Solid Tumors\nEstima
 ted primary completion: 3 May 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05836324
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07863869-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20290527
DTEND;VALUE=DATE:20290528
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT07863869)
DESCRIPTION:Cetuximab\, phase 1/2.\nStudy: The QL1706 Combined With Chemoth
 erapy and Either Cetuximab or Bevacizumab in Potentially Resectable Colore
 ctal Cancer Patients With Liver Metastases\nEstimated primary completion: 
 27 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuxima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 863869
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05863195-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Cetuximab: Phase 3 readout est. (NCT05863195)
DESCRIPTION:Cetuximab\, phase 3.\nStudy: Testing Pump Chemotherapy in Addit
 ion to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy 
 Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP
  Trial\nEstimated primary completion: 30 June 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05863195
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07535112-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20290727
DTEND;VALUE=DATE:20290728
SUMMARY:Cetuximab: Phase 1 readout est. (NCT07535112)
DESCRIPTION:Cetuximab\, phase 1\, Metastatic Colorectal Cancer.\nStudy: A S
 tudy to Learn More About How Safe BAY 3771249 is and How Well it Works in 
 People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D 
 Mutation\nEstimated primary completion: 27 July 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07535112
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05203172-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Cetuximab: Phase 4 readout est. (NCT05203172)
DESCRIPTION:Cetuximab\, phase 4.\nStudy: The FLOTILLA Study: Providing Cont
 inued Access to The Study Medicines Encorafenib and Binimetinib for Partic
 ipants in Prior Clinical Trials\nEstimated primary completion: 31 July 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05203172
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07790510-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT07790510)
DESCRIPTION:Cetuximab\, phase 1/2\, Metastatic Colorectal Cancer.\nStudy: H
 SK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in
  BRAF V600-Mutant Metastatic Colorectal Cancer\nEstimated primary completi
 on: 30 September 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/cetuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07790510
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06647563-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Cetuximab: Phase 3 readout est. (NCT06647563)
DESCRIPTION:Cetuximab\, phase 3\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advan
 ced Head and Neck Squamous Cell Carcinoma (Neo-ICT)\nEstimated primary com
 pletion: 30 September 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/cetuximab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06647563
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04587128-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT04587128)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: Ear
 ly-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients Wi
 th mCRC\nEstimated primary completion: October 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04587128
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05956821-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT05956821)
DESCRIPTION:Cetuximab\, phase 1/2.\nStudy: Treatment of Relapsed/Refractory
  Intracranial Glioma in Patients Under 22 Years of Age\nEstimated primary 
 completion: 1 October 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/cetuximab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05956821
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621497-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07621497)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: FOL
 FOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresect
 able Metastatic Colorectal Cancer (Phase II)\nEstimated primary completion
 : 1 November 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ce
 tuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07621497
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07939815-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20291229
DTEND;VALUE=DATE:20291230
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT07939815)
DESCRIPTION:Cetuximab\, phase 1/2.\nStudy: A Study of BMS-986548 as Monothe
 rapy and in Combination With Anti-cancer Agents in Participants With Advan
 ced Solid Malignancies\nEstimated primary completion: 29 December 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07939815
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07030959-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Cetuximab: Phase 1 readout est. (NCT07030959)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: Study of AUBE00 in Patients With S
 olid Tumors\nEstimated primary completion: 31 December 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07030959
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07789210-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07789210)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: A Single-Arm\, Phase II\, Multicen
 ter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLF
 OX6 in Patients With Locally Advanced BRAF V600E-Mutant Colorectal Cancer 
 With or Without Resectable Metastases\nEstimated primary completion: 31 De
 cember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuxima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 789210
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05226871-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT05226871)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Study for Participants Continuing From Pfizer-sponsored Palbociclib 
 (a Study Medicine) Studies\nEstimated primary completion: 31 December 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05226871
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05067283-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20300225
DTEND;VALUE=DATE:20300226
SUMMARY:Cetuximab: Phase 1 readout est. (NCT05067283)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: A Study of Calderasib (MK-1084) in
  KRAS Mutant Advanced Solid Tumors (MK-1084-001)\nEstimated primary comple
 tion: 25 February 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/cetuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05067283
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07183865-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20300309
DTEND;VALUE=DATE:20300310
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07183865)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Hypofractionated Radiotherapy Comb
 ined With NALIRIF\, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVEL
 TY-R)\nEstimated primary completion: 9 March 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07183865
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06928584-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20300310
DTEND;VALUE=DATE:20300311
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06928584)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Hypofractionated Radiotherapy Plus
  Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Recta
 l Cancer\nEstimated primary completion: 10 March 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06928584
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897721-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20300322
DTEND;VALUE=DATE:20300323
SUMMARY:Cetuximab: Phase 1 readout est. (NCT07897721)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: A Study to Learn About the Study M
 edicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metas
 tatic Solid Tumors\nEstimated primary completion: 22 March 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07897721
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07733466-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07733466)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Open-Label Neoadjuvant Pembrolizum
 ab Plus Cetuximab in Betel Nut-Associated Locally Advanced Oral Cavity Squ
 amous Cell Carcinoma\nEstimated primary completion: July 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07733466
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06418724-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20300730
DTEND;VALUE=DATE:20300731
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06418724)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Neoadjuvant PD-1 Inhibitor and EGF
 R Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma\nEstimat
 ed primary completion: 30 July 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06418724
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04929223-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Cetuximab: Phase 1 readout est. (NCT04929223)
DESCRIPTION:Cetuximab\, phase 1\, Metastatic Colorectal Cancer.\nStudy: A S
 tudy Evaluating the Safety and Efficacy of Targeted Therapies in Subpopula
 tions of Patients With Metastatic Colorectal Cancer (INTRINSIC)\nEstimated
  primary completion: 31 August 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04929223
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389265-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Cetuximab: Phase 3 readout est. (NCT07389265)
DESCRIPTION:Cetuximab\, phase 3\, Metastatic Colorectal Cancer.\nStudy: Con
 tinuation of Cetuximab Beyond First-Line Progression in Metastatic Colorec
 tal Cancer\nEstimated primary completion: October 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07389265
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07247110-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Cetuximab: Phase 1 readout est. (NCT07247110)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: A Clinical Study of MK-4716 in Peo
 ple With Certain Solid Tumors (MK-4716-001)\nEstimated primary completion:
  1 December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cet
 uximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07247110
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06988852-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06988852)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: FOLFOX-HAIC as Conversion Treatmen
 t for Initially Unresectable Colorectal Liver Metastasis\nEstimated primar
 y completion: 31 December 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06988852
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07432087-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Cetuximab: Phase 3 readout est. (NCT07432087)
DESCRIPTION:Cetuximab\, phase 3\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy 
 for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cel
 l Carcinoma\nEstimated primary completion: 31 December 2030. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07432087
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07381764-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20310330
DTEND;VALUE=DATE:20310331
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07381764)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: ROM
 ANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil
  Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"\nE
 stimated primary completion: 30 March 2031. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07381764
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07715734-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07715734)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Cemiplimab for Kidney Transplant R
 ecipients With Advanced Cutaneous Squamous Cell Carcinoma\nEstimated prima
 ry completion: 30 April 2031. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07715734
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509099-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Cetuximab: Phase 3 readout est. (NCT07509099)
DESCRIPTION:Cetuximab\, phase 3\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemothera
 py in R/M HNSCC\nEstimated primary completion: 30 September 2031. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07509099
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07204340-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20311203
DTEND;VALUE=DATE:20311204
SUMMARY:Cetuximab: Phase 1 readout est. (NCT07204340)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: TLN-372 in Advanced KRAS Mutant So
 lid Tumors\nEstimated primary completion: 3 December 2031. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07204340
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02128906-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20311216
DTEND;VALUE=DATE:20311217
SUMMARY:Cetuximab: Phase 2 readout est. (NCT02128906)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Radiotherapy With Cisplatin vs. Do
 cetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Des
 ign\nEstimated primary completion: 16 December 2031. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT02128906
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07905924-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20320330
DTEND;VALUE=DATE:20320331
SUMMARY:Cetuximab: Phase 1 readout est. (NCT07905924)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: A Study to Evaluate the Safety and
  Effectiveness of Different Doses of RO7836748 Alone or in Combination Wit
 h Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Vi
 ral Oncogene Homolog Glycine 12 Valine (RAS G12V) Mutation\nEstimated prim
 ary completion: 30 March 2032. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07905924
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07209111-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20320409
DTEND;VALUE=DATE:20320410
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07209111)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: A Clinical Study of Calderasib (MK
 -1084) in People With Advanced Solid Tumors (MK-1084-014)\nEstimated prima
 ry completion: 9 April 2032. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/cetuximab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07209111
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07926334-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20321105
DTEND;VALUE=DATE:20321106
SUMMARY:Cetuximab: Phase 1 readout est. (NCT07926334)
DESCRIPTION:Cetuximab\, phase 1.\nStudy: A Study of BI 4015092\, Alone or i
 n Combination With Other Cancer Treatment\, in Patients With Advanced Canc
 er That Has a KRAS G12D Mutation\nEstimated primary completion: 5 November
  2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07926334
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06589804-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20321225
DTEND;VALUE=DATE:20321226
SUMMARY:Cetuximab: Phase 3 readout est. (NCT06589804)
DESCRIPTION:Cetuximab\, phase 3\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Testing the Addition of Anti-Cancer Drug\, Cetuximab\, to Standard o
 f Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck 
 Cancer After Previous Treatment\nEstimated primary completion: 25 December
  2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06589804
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05710406-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20340601
DTEND;VALUE=DATE:20340602
SUMMARY:Cetuximab: Phase 2/3 readout est. (NCT05710406)
DESCRIPTION:Cetuximab\, phase 2/3.\nStudy: Testing the Use of BRAF-Targeted
  Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cance
 r\nEstimated primary completion: 1 June 2034. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05710406
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02800486-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20350531
DTEND;VALUE=DATE:20350601
SUMMARY:Cetuximab: Phase 2 readout est. (NCT02800486)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: Super Selective Intra-arterial Rep
 eated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of 
 Relapsed/Refractory GBM\, AA\, and AOA\nEstimated primary completion: May 
 2035. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT02800486
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441681-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20351130
DTEND;VALUE=DATE:20351201
SUMMARY:Cetuximab: Phase 3 readout est. (NCT07441681)
DESCRIPTION:Cetuximab\, phase 3\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in
  People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin\nE
 stimated primary completion: 30 November 2035. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07441681
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05725200-1965@assetmemo.bio
DTSTAMP:20261121T004102Z
DTSTART;VALUE=DATE:20381231
DTEND;VALUE=DATE:20390101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT05725200)
DESCRIPTION:Cetuximab\, phase 2\, Metastatic Colorectal Cancer.\nStudy: Stu
 dy to Investigate Outcome of Individualized Treatment in Patients With Met
 astatic Colorectal Cancer\nEstimated primary completion: 31 December 2038.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05725200
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
